NEW RESOURCE: CHEMICAL SLAVERY AVAILABLE AT AMAZON.COM
At a time when the nation is searching for ways to save lives from opioid and other drug overdoses as well as how to reduce the burden of addiction on individuals, families and communities, IBH President Robert L. DuPont, MD has written Chemical Slavery: Understanding Addiction and Stopping the Drug Epidemic, for parents, teachers, physicians and for everyone afflicted by addiction. The book also guides leaders in public policy and planning positions, as well as drug abuse treatment. Dr. DuPont is President of the Institute for Behavior and Health and served as the first Director of the National Institute on Drug Abuse. Available at Amazon.com.
IBH has published the following reports in conjunction with meetings and symposia, bringing together leaders in the relevant fields who subsequently contributed to and provided feedback on the content of these reports through IBH-convened working committees.
Facing Addiction in America: The Surgeon General's Report on Alcohol, Drug Abuse and Health - A New Agenda to Turn Back the Drug Epidemic (May 2017)
A Strategy to Assess the Consequences of Marijuana Legalization (December 2016)
State of the Art of HOPE Probation (September 2015)
HOPE-Like Probation and Parole: 2015 Survey Summary (September 2015)
The HOPE Probation Strategy and Fidelity to It: A Summary (September 2015)
Workplace Drug Testing in the Era of Legal Marijuana (March 2015)
Creating a New Standard for Addiction Treatment Outcomes (August 2014)
The New Paradigm for Recovery (March 2014)
America’s Dropout Crisis: The Unrecognized Connection to Adolescent Substance Use (March 2013)
Drugged Driving Research: A White Paper (March 2011)
IBH publishes commentaries that analyze problems of drug use and propose solutions for them.
Reducing Future Rates of Adult Addiction Must Begin with Youth Prevention (updated August 29, 2018)
For a Healthy Brain Teens Make "One Choice" (October 23, 2017)
Going Beyond the Surgeon General’s Report: Redefining the Goals of Prevention, Treatment and Recovery (January 30, 2017) Implement Effective DUID Laws to Improve Highway Safety (October 12, 2016)
Getting Serious about Substance Abuse Treatment Requires Adopting the Five-Year Recovery Standard (May 26, 2016)
A Four-Point Plan to Turn Back the Deadly Epidemic (March 3, 2016)
With Marijuana Legalization, There is More Marijuana Use and More Addiction While the Illegal Market Continues to Thrive (December 21, 2015)
It's Time to Re-Think Prevention: Increasing Percentages of Adolescents Understand They Should Not Use Any Addicting Substances (July 1, 2015)
Colorado Supreme Court Provides a Moment of Sanity on Marijuana (June 30, 2015)
Drug Addicts and Their Families are Showing the Way to a Better National Drug Policy (April 28, 2015)
While the US Zigs on Pot, the Netherlands Zags (March 19, 2015)
“Vaping” – The Transformation of Marijuana (December 18, 2014)
Addressing the Results of Marijuana Ballot Initiatives in the November 2014 US Elections (November 7, 2014) - Extended Commentary
Random Drug Testing Protects Patients and Medical Personnel (August 4, 2014)
The Changing State of Drug Policy (July 23, 2014)
A Definitive Summary of the Adverse Effects of Marijuana Use: Implications for Public Policy (June 11, 2014)
Marijuana Use is a Serious Highway Safety Threat: 5 ng/ml Marijuana Impairment Limits Give Drivers a Free Pass to Drive Stoned (June 10, 2013)
“Psychedelic Medicine” – The Next Frontier in Drug Legalization (May 17, 2013)
Washington’s Double Failure: Failure of Department of Justice to Enforce Federal Law, Failure of Senate Judiciary Committee to Hold DOJ Accountable (March 25, 2013)
Lessons from a Tragedy – Mexican Drug Violence Claims an Unbowed Martyr. Joint Commentary with Per Johansson and Carmen Fernández Cáceres (January 21, 2013)
JOURNAL ARTICLES AND OTHER PROFESSIONAL PUBLICATIONS BY SUBJECT
DuPont, R. L., Garcia-Rosales, K., Shea, C. L., DuPont, H., Campbell, M. D., Kolodner, G., & Wish, E. (2017). Are prescription opioids creating a new type of heroin user? The Journal of Global Drug Policy and Practice, 11(1).
DuPont, R. L. (2016). Getting serious about substance abuse treatment requires adopting the five-year recovery standard. Journal of Global Drug Policy and Practice, 10(3).
DuPont, R. L. (2016, September 12). Benzodiazepines and addiction: new thinking about old drugs. Kolmac Outpatient Recovery Centers Blog.
Campbell, M. D., Kolodner, G., Spencer, R. A. & DuPont, R. L. (2016). Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program. Journal of Addictive Diseases.
DuPont, R. L., Seppala, M. D. & White, W. L. (2015). The three missing elements in the treatment of substance use disorders: lessons from the physician health programs. Journal of Addictive Diseases, 35(1), 3-7.
DuPont, R. L., Compton, W. M. & McLellan, A. T. (2015). Five-year recovery: A new standard for assessing effectiveness of substance use disorder treatment. Journal of Substance Abuse Treatment, 58, 1-5.
White, W. L., Campbell, M. D., Spencer, R. D., Hoffman, H. A., Crissman, B., & DuPont, R. L. (2014). Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. Journal of Psychoactive Drugs, 46(2), 114-122.
White, W. L., Campbell, M. D., Spencer, R. A., Hoffman, H. A., Crissman, B., & DuPont, R. L. (2014). Participation in Narcotics Anonymous and Alcoholics Anonymous and abstinence outcomes of 322 methadone maintenance patients. Journal of Groups in Addiction & Recovery, 9(1), 14-30.
Physician Health Programs
DuPont, R. L., & Merlo, L. J. (2018). Physician health programs: a model for treating substance use disorders. The Judges’ Journal, 57(1), 32-35.
Carr, G. D., Hall, B., Finlayson, A. J. R., & DuPont, R. L. (2017). Physician health programs: the US model. In K. J. Brower & M. B. Riba (Eds.), Physician Mental Health and Well-Being: Integrating Psychiatry and Primary Care (pp. 265-294). Cham, Switzerland: Springer International Publishing.
Merlo, L. J., & DuPont, R. L. (2016). Essential components of physician health program participation: perspectives of participants five years post-graduation. Physician Health News, 1, 14-15.
Merlo, L. J., Campbell, M. D., Skipper, G. E., Shea, C. L., & DuPont, R. L. (2016). Outcomes for physicians with opioid dependence treated without agonist pharmacotherapy in physician health programs. Journal of Substance Abuse Treatment, 64, 47-54.
Finlayson, A. J. R., Iannelli, R. J., Brown, K. P., Neufeld, R. E., DuPont, R. L., & Campbell, M. D. (2016). Physician suicide and physician health programs. General Hospital Psychiatry.
DuPont, R. L. (2016). An outsider looks at PHP care management. Physician Health News, 21, 7-8.
Braquehais, M. D., Tresidder, A. & DuPont, R. L. (2015). Service provision to physicians with mental health and addiction problems. Current Opinion in Psychiatry, 28(4), 324-329.
Rose, J. S., Campbell, M. D., & Skipper, G. E. (2014). Prognosis for emergency physician with substance abuse recovery: 5-year outcome study. Western Journal of Emergency Medicine, 15(1).
Yellowlees, P. M., Campbell, M. D., Rose, J. S., Parish, M. B., Ferrer, D., Scher, L. M., Skipper, G. E., & DuPont, R. L. (2014). Psychiatrists with substance use disorders: positive treatment outcomes from physician health programs. Psychiatric Services, doi: 10.1176/appi.ps.201300472
DuPont, R. L., & Skipper, G. E. (2012). Six lessons from physician health programs to promote long-term recovery. Journal of Psychoactive Drugs, 44(1), 72-78.
Buhl, A., Oreskovich, M. R., Meredith, C. W., Campbell, M. D., & DuPont, R. L. (2011). Prognosis for the recovery of surgeons from chemical dependency. Archives of Surgery, 146(11), 1286-1291.
Skipper, G. E., Campbell, M. D. & DuPont, R. L. (2009). Anesthesiologists with substance use disorders: A 5-year outcome study from 16 state Physician Health Programs. Anesthesia & Analgesia, 109(3), 891-896.
DuPont, R. L., McLellan, A. T., Carr, G., Gendel, M & Skipper, G. E. (2009). How are addicted physicians treated? A national survey of physician health programs. Journal of Substance Abuse Treatment, 37, 1-7.
DuPont R. L., McLellan A. T., White W. L., Merlo L., and Gold M. S. (2009). Setting the standard for recovery: Physicians Health Programs evaluation review. Journal for Substance Abuse Treatment, 36(2), 159-171.
McLellan, A. T., Skipper, G. E., Campbell, M. G. & DuPont, R. L. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. British Medical Journal, 337:a2038.
Larkin, P. J., DuPont, R. L., & Madras, B. K. (2018, May 16). The Need to Treat Driving Under the Influence of Drugs as Seriously as Driving Under the Influence of Alcohol. Backgrounder, 3316. Washington, DC: The Heritage Foundation.
Talpins, S. K., DuPont, R. L., Walls, C. H., Sabet, K., & Wallace, D. (2015). The Miami-Dade protocol: making drugged driving enforcement a reality. Journal of Alcohol and Drug Dependence, 3(4), 212-213.
DuPont, R. L., & Shea, C. L. (2014, August). The public safety threat of drugged driving. Need to Know. Alexandria, VA: National Association of Drug Court Professionals.
Talpins, S. K., DuPont, R. L, Voas, R. B., Holmes, E., Sabet, K. A., & Shea, C. L. (2014). License to revocation as a tool for combating drugged driving. Impaired Driving Update, 18(2).
DuPont, R. L, Talpins, S. K., & Shea, C. L. (2013). Commentary on Romano & Pollini (2013): Stopping drug-impaired driving and alcohol-impaired driving—synergy, not competition. Addiction, 108(8), 1439-1440.
Voas, R. B., DuPont, R. L., Shea, C. L., & Talpins, S. K. (2013). Prescription drugs, drugged driving and per se laws. Injury Prevention, 19(3), 218-221.
Reisfield, G. M., Goldberger, B. A., Gold, M. S., & DuPont, R. L. (2012). The mirage of impairing drug concentration thresholds: A rationale for zero tolerance per se driving under the influence of drugs laws. Journal of Analytical Toxicology, 36(5), 353-356.
DuPont, R. L., Voas, R. B., Walsh, J. M., Shea, C., Talpins, S. K., & Neil, M. M. (2012). The need for drugged driving per se laws: A commentary. Traffic Injury Prevention, 13(1), 31-42.
National Drug Trends and Policy
DuPont, R. L. (2018). A new narrative to understand the opioid epidemic. The Journal of Global Drug Policy and Practice, 12(1).
Han, B., Compton, W. M., Blanco, C., & DuPont, R. L. (2017). National trends in substance use and use disorders among youth. Journal of the American Academy of Child & Adolescent Psychiatry, 56(9), 747-754.
Bennett, W., & DuPont, R. L. (2017, June 29). Getting the opioid epidemic right. The Daily Signal.
DuPont, R. L. (2016, April 26). Marijuana has proven to be a gateway drug [Room for Debate]. The New York Times.
DuPont, R. L. (2015). The global drug problem: an introduction. In Drug Policy Futures, Future of Drug Policy: Real Solutions Grounded in Global Evidence (pp. 7-9). Stockholm, Sweden: Drug Policy Futures.
Wish, E. D., Artigiani, E., Billing, A., Hauser, W., Hemberg, J., Shiplet, M., DuPont, R. L. (2012). The emerging buprenorphine epidemic in the United States. Journal of Addictive Diseases, 31(1), 3-7.
DuPont, R. L., Madras, B. K. & Johansson, P. (2011). Drug policy: a biological science perspective. In J. H. Lowinson & P. Ruiz (Eds.) Substance Abuse: A Comprehensive Textbook (5th ed., pp. 998-1010). Philadelphia, PA: Lippincott Williams & Wilkins.
Drug and Alcohol Testing
DuPont, R. L. (2017, July/August). New trends in workforce drug use. Risk Management, 14-15.
DuPont, R. L. (2015, Fall). Drug testing and legal marijuana: What should contractors do? The Construction User, 14-15, 23.
Skipper, G. E., Thon, N., DuPont, R. L., Campbell, M. D., Weinmann, W., & Wurst, F. M. (2014). Cellular photo digital for monitoring alcohol use: a pilot study. European Addiction Research, 20(3), 137-142.
Skipper, G. E., Thon, N., DuPont, R. L., Baxter, L., & Wurst, F. M. (2013). Phosphatidylethanol: the potential role in further evaluating low positive urinary ethyl glucuronide and ethyl sulfate results. Alcoholism, Clinical and Experimental Research, 37(9), 1582-158.
DuPont, R. L., Martin, D. M., & Skipper, G. E. (2012). A new challenge for drug-free workplace programs. Occupational Health and Safety, 81(2).
Reisfield, G. M., Shults, T., Demery, J., & DuPont, R. L. (2013). A protocol to evaluate drug-related workplace impairment. Journal of Pain and Palliative Care Pharmacotherapy, 27(1), 43-48.
Morrison, R. A., & DuPont, R. L. (2013). The new paradigm and the DOT/SAP process. Journal of Employee Assistance, 43(1), 26-28.
Levy, S., Campbell, M. C., Shea, C. L., & DuPont, R. L. (2018). Trends in abstaining from substance use in adolescents: 1975-2014. Pediatrics, doi: 10.1542/peds.2017-3498.
DuPont, R. L., Han, B., Shea, C. L., & Madras, B. K. (2018). Drug use among youth: national survey data support a common liability of all drug use. Preventive Medicine, 113, 68-73.
DuPont, R. L. (2017). The opioid epidemic is an historic opportunity to improve both prevention and treatment. Brain Research Bulletin.
Levy, S., DuPont, R. L., Fishman, M. J., & Hadland, S. (2017, September 28). Teen substance use declining, but addiction persists. Thrive Global.
DuPont, R. L. (2016, May 23). Drug abuse prevention should be about health: no use of alcohol, nicotine, marijuana and other drugs for reasons of health. CADCA Blog.
DuPont, R. L., Merlo, L. J., Arria, A. M., & Shea, C. L. (2013). Random student drug testing as a school-based drug prevention strategy. Addiction, 108(5), 839-845.
DuPont, R. L., Campbell, M. D., Campbell, T. G., Shea, C. L., & DuPont, H. S. (2013). Self-reported drug and alcohol use and attitudes toward drug testing in high school with random student drug testing. Journal of Child & Adolescent Substance Abuse, 22(2), 104-119.
DuPont, R.L., & Bucher, R.H. (2012). Guide to responsible family drug and alcohol testing. Rockville, MD: Institute for Behavior and Health, Inc.
DuPont, R. L. (2016, August 25). Should patients with cancer be offered cannabis as a pain management strategy? No. [Point/Counter]. HemOnc Today.
Reisfield, G. M., & DuPont, R. L. (2013). Recommend against the medicinal use of marijuana [Clinical Decisions]. New England Journal of Medicine, 368(9), 886-868.
Kleber, H. D., & DuPont, R. L. (2012). Physicians and medical marijuana. American Journal of Psychiatry, 169(6), 564-568.